Atopic dermatitis

Disease ID:94
Name:Atopic dermatitis
Associated with:2 targets
1 immuno targets immuno relevant
15 immuno ligands
Database Links
Disease Ontology: DOID:3310
OMIM: 603165


BLT1 receptor
References:  9
Comments:  Target of activating compounds with potential immunosuppressant action. Phase 2 with rosiptor has been completed for atopic dermatitis.
Immuno ligand interactions
Ligand Name Disease Association Comments Approved Primary Target Immuno
Phase 2 clinical trial NCT02324972 completed.


Ligand Approved Immuno References Clinical comments
Clinical Use: Tralokinumab reached Phase 3 clinical trials for uncontrolled asthma, and atopic dermatitis, and Phase 2 for alopecia areata. Click here to link to's listing of Phase III tralokinumab trials. In addition, Phase 2 trials are investigating tralokinumab as a treatment for idiopathic pulmonary fibrosis (IPF, NCT01629667 and NCT02036580). Business reports online indicate that AstraZeneca have discontinued tralokinumab development as it showed no benefit over placebo in their STRATOS 2 and TROPOS late-stage asthma trials [1].
Immuno Disease Comments: Phase 3 clinical candidate for atopic dermatitis (see NCT03131648).
Clinical Use: A Phase 3 clinical study evaluating PAC-14028 vs. atopic dermatitis is underway (see NCT02965118). Phase 2 studies for rosacea, seborrheic dermatitis and skin pruritus have been completed.
Immuno Disease Comments: Phase 3 clinical candidate for atopic dermatitis.
Clinical Use: A Phase 2 clinical trial evaluating ALX-101 as a topical treatment for moderate atopic dermatitis is underway (see NCT03175354).
Immuno Disease Comments: Phase 2 clinical candidate for atopic dermatitis.
Clinical Use: Topically applied tapinarof (research code GSK2894512) has shown clinical efficacy in Phase 2 clinical trial in patients with plaque psoriasis [3] (NCT02564042). A Phase 3 trial (NCT03202004) is ready to recruit subjects (Oct 2017). Tapinarof has also completed Phase 1 studies for atopic dermatitis.
Immuno Disease Comments: Phase 1 clinical candidate for atopic dermatitis- NCT02466152
Clinical Use: OPA-15406 has completed Phase 2 clinical trials in adult and pediatric patients with atopic dermatitis. Click here to view's registered OPA-15406 trials. Positive Phase 2 trial results are published by Hanifin et al. (2016) [5].
Immuno Disease Comments: Phase 2 clinical candidate for atopic dermatitis- see NCT02914548
cortisol  [ FDA (1953, prior history unavailable) ( ]
Clinical Use: Hydrocortisone is used to treat many immune and allergic disorders, adrenal insufficiency disorders (eg Addison's disease) and corticosteroid-responsive dermatological disorders (eg psoriasis, atopic dermatitis, and contact dermatitis).
Immuno Disease Comments: Glucocorticoid drug used to treat many inflammatory condtions including allergic dermatitis.
Immuno Disease Comments: IL-31 expression is elevated in inflammatory cells in atopic dermatitis.
dupilumab  [ EMA & FDA (2017) ( ]
Clinical Use: Dupilumab is being clinically assessed as a treatment for atopic allergic conditions, including asthma, atopic dermatitis (AD) and nasal polyposis. A list of trials registered at is available here.
Preliminary results from one clinical trial in patients with persistent asthma, reports significant improvements in measures of lung function and asthma control when treated with dupilumab [10].
Results from a Phase II study in patients with nasal polyposis and chronic symptoms of sinusitis (NCT01920893) are reported by Bachert et al. (2016) [2]. Patients in this study were given dupilumab + mometasone or mometasone + dupilumab placebo. Dupilumab + mometasone reduced nasal polyp burden and improved symptoms of sinusitis to a greater extent than the mometasone + placebo treatment.
Dupilumab received full FDA approval for moderate-to-severe eczema (atopic dermatitis) in March 2017, and the EMA granted this same approval in August 2017.
Immuno Disease Comments: Dupilumab is approved to treat atopic dermatitis (eczema).
Clinical Use: Tezepelumab is being evaluated in clinical trials as a potential immunomodulatory agent for uncontrolled (especially noneosinophilic type) asthma (Phase 2- results of NCT02054130 published in [4]) and atopic dermatitis (AD; Phase 1). Click here to link to's full listing of tezepelumab (research coded AMG 157 or MEDI9929) trials.
Immuno Disease Comments: Clinical candidate for atopic dermatitis (Phase 1).
JNJ-39758979 6-7
Clinical Use: Phase 2a clinical trial results in patients with moderate atopic dermatitis are published in [7] which indicate that the study did not meet its primary end-point, and produced drug-induced agranulocytosis, explaining its termination. Phase 2 trial NCT00946569 in asthma patients has been completed.
Immuno Disease Comments: Failed to show clinical efficiency in Phase 2 trial.
Clinical Use: ZPL-3893787 has reached Phase 2 clinical trial for evaluation as an antiinflammatory agent in patients with plaque psoriasis (see NCT02618616), and a Phase 1 in atopic dermatitis has been completed.
Immuno Disease Comments: Completed Phase 2 trial in atopic dermatitis (see NCT02424253).
crisaborole  [ FDA (2016) ( ]
Clinical Use: Crisaborole (with research code AN2728) has completed Phase 3 clinical trials as a monotherapy for atopic dermatitis (NCT02118792 and NCT02118766) and has received FDA approval for treatment of mild-to-moderate atopic dermatitis in December 2016.
Immuno Disease Comments: Approved drug for atopic dermatitis.
Clinical Use: AQX-1125 has reached Phase 2 clinical trial in chronic inflammatory conditions such as unstable chronic obstructive pulmonary disease (COPD) and atopic dermatitis, and Phase 3 for interstitial cystitis/bladder pain syndrome [8] (see NCT02858453). Click here to link to's full list of AQX-1125 trials.
Immuno Disease Comments: Phase 2 clinical trial NCT02324972 completed.
Clinical Use: OC000459 is being evaluated in several Phase 2 clinical trials in various inflammatory and allergic conditions including asthma, allergic rhinitis and atopic dermatitis. Click here to link to a list of Phase 2 OC000459 trials registered with
Immuno Disease Comments: Phase 2 clinical candidate for atopic dermatitis.
Clinical Use: Fezakinumab (ILV-094) has reached Phase 2 for atopic dermatitis (NCT01941537 ongoing), rheumatoid arthritis (NCT00883896 completed) and Phase 1 for psoriasis (NCT00563524 completed).
Immuno Disease Comments: Active Phase 2 study NCT01941537.


Show »

1. Adams B. Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease. Accessed on 09/02/2018. Modified on 09/02/2018.,

2. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR et al.. (2016) Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA315 (5): 469-79. [PMID:26836729]

3. Bissonnette R, Bolduc C, Maari C, Nigen S, Webster JM, Tang L, Lyle M. (2012) Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol26 (12): 1516-21. [PMID:22077962]

4. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R. (2017) Tezepelumab in Adults with Uncontrolled Asthma. N. Engl. J. Med.377 (10): 936-946. [PMID:28877011]

5. Hanifin JM, Ellis CN, Frieden IJ, Fölster-Holst R, Stein Gold LF, Secci A, Smith AJ, Zhao C, Kornyeyeva E, Eichenfield LF. (2016) OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. J. Am. Acad. Dermatol.75 (2): 297-305. [PMID:27189825]

6. Kollmeier A, Francke K, Chen B, Dunford PJ, Greenspan AJ, Xia Y, Xu XL, Zhou B, Thurmond RL. (2014) The histamine H₄ receptor antagonist, JNJ 39758979, is effective in reducing histamine-induced pruritus in a randomized clinical study in healthy subjects. J. Pharmacol. Exp. Ther.350 (1): 181-7. [PMID:24817035]

7. Murata Y, Song M, Kikuchi H, Hisamichi K, Xu XL, Greenspan A, Kato M, Chiou CF, Kato T, Guzzo C et al.. (2015) Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J. Dermatol.42 (2): 129-39. [PMID:25491792]

8. Nickel JC, Egerdie B, Davis E, Evans R, Mackenzie L, Shrewsbury SB, collaborative. (2016) A Phase II Study of the Efficacy and Safety of the Novel Oral SHIP1 Activator AQX-1125 in Subjects with Moderate to Severe Interstitial Cystitis/Bladder Pain Syndrome. J. Urol.,  [Epub ahead of print]. [PMID:26968644]

9. Oyoshi MK, He R, Li Y, Mondal S, Yoon J, Afshar R, Chen M, Lee DM, Luo HR, Luster AD et al.. (2012) Leukotriene B4-driven neutrophil recruitment to the skin is essential for allergic skin inflammation. Immunity37 (4): 747-58. [PMID:23063331]

10. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B et al.. (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med.368 (26): 2455-66. [PMID:23688323]